Pierrel SpA banner
P

Pierrel SpA
MIL:PRL

Watchlist Manager
Pierrel SpA
MIL:PRL
Watchlist
Price: 1.745 EUR
Market Cap: €95.9m

Relative Value

There is not enough data to reliably calculate the relative value of PRL.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PRL Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Multiples Across Competitors

PRL Competitors Multiples
Pierrel SpA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IT
Pierrel SpA
MIL:PRL
95.9m EUR 2.9 30.6 17.6 31.7
US
Eli Lilly and Co
NYSE:LLY
976.4B USD 15 47.3 31.9 33.9
US
Johnson & Johnson
NYSE:JNJ
590.4B USD 6.3 22 15.3 18.8
CH
Roche Holding AG
SIX:ROG
294.6B CHF 4.8 31.1 13.1 15.3
CH
Novartis AG
SIX:NOVN
248.5B CHF 5.7 22.8 14.1 18.1
UK
AstraZeneca PLC
LSE:AZN
236B GBP 5.4 31 17.1 24.2
US
Merck & Co Inc
NYSE:MRK
306.5B USD 4.7 16.8 10.5 12.3
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 3.5 10.4 7.7 9.1
US
Pfizer Inc
NYSE:PFE
154.2B USD 2.5 19.8 7.4 9.9
US
Bristol-Myers Squibb Co
NYSE:BMY
123.7B USD 2.6 17.5 7.3 9
P/E Multiple
Earnings Growth PEG
IT
P
Pierrel SpA
MIL:PRL
Average P/E: 24.9
30.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
47.3
28%
1.7
US
Johnson & Johnson
NYSE:JNJ
22
7%
3.1
CH
Roche Holding AG
SIX:ROG
31.1
29%
1.1
CH
Novartis AG
SIX:NOVN
22.8
15%
1.5
UK
AstraZeneca PLC
LSE:AZN
31
26%
1.2
US
Merck & Co Inc
NYSE:MRK
16.8
14%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.4
7%
1.5
US
Pfizer Inc
NYSE:PFE
19.8
26%
0.8
US
Bristol-Myers Squibb Co
NYSE:BMY
17.5
17%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IT
P
Pierrel SpA
MIL:PRL
Average EV/EBITDA: 44.3
17.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
31.9
18%
1.8
US
Johnson & Johnson
NYSE:JNJ
15.3
2%
7.6
CH
Roche Holding AG
SIX:ROG
13.1
5%
2.6
CH
Novartis AG
SIX:NOVN
14.1
9%
1.6
UK
AstraZeneca PLC
LSE:AZN
17.1
11%
1.6
US
Merck & Co Inc
NYSE:MRK
10.5
7%
1.5
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.7
7%
1.1
US
Pfizer Inc
NYSE:PFE
7.4
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.3
-12%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IT
P
Pierrel SpA
MIL:PRL
Average EV/EBIT: 95.2
31.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
33.9
17%
2
US
Johnson & Johnson
NYSE:JNJ
18.8
6%
3.1
CH
Roche Holding AG
SIX:ROG
15.3
6%
2.5
CH
Novartis AG
SIX:NOVN
18.1
12%
1.5
UK
AstraZeneca PLC
LSE:AZN
24.2
24%
1
US
Merck & Co Inc
NYSE:MRK
12.3
6%
2
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.1
8%
1.1
US
Pfizer Inc
NYSE:PFE
9.9
-1%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
9
-6%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett